Crohn’s Disease Treatment Market, 2012-2023

January 2018 | 201 pages | ID: C4B674918E7EN
Precision Business Insights (PBI)

Abstracts

Global Crohn’s Disease Treatment Market

Crohn’s disease belongs to a condition called inflammatory bowel disease (IBD) that causes inflammation and damage to the digestive tract. Crohn’s disease usually affects at the end of small intestine and beginning of colon, but inflammation may occur anywhere along the digestive tract. Crohn’s disease may be hereditary or develop due to the malfunctioning of the immune system. Currently there is no cure for crohn’s disease. However, there are many treatments to manage disease symptoms. Inflammation, ulcers, bowel obstruction, malnutrition, colon cancer, and anal fissures are some of the complications associated with the disease. Surgery and drug therapy are some of the treatment options available to treat Crohn’s disease. Some of the anti-inflammatory drugs used to treat crohn’s disease include, corticosteroids and oral 5-aminosalicylates.

The prime driver for Crohn’s disease treatment market is increase in number of people being infected by the disease. In addition, increase in demand for biologics and high unmet needs within the anti-TNF refractory patient group that presents untapped market opportunities. Strong pipeline and novel mechanisms to treat Crohn’s disease are fuelling the growth of Crohn’s disease treatment market. However, patent expiry of the key drugs and high cost of treatment is expected to hamper the Crohn’s disease treatment market globally. High R&D investment for development of biological drugs and unknown aetiology of the Crohn’s disease further hindering the market growth.

Global Crohn’s disease treatment market is segmented based on, drug class and distribution channel

Based on drug class, Crohn’s disease treatment market is segmented into

• Antibiotics
• Anti-Diarrheal
• Immune System Suppressants
• Analgesics
• Anti-Inflammatory Drugs
• Monoclonal Antibodies

Based on distribution channel, Crohn’s disease treatment market is segmented into

• Hospital Pharmacy
• Retail Pharmacy
• Others

Crohn’s disease treatment market is expected to grow at a significant rate during the forecast period. Growth in biologics development unfolded the opportunities for the new market players as they are most commonly used in Crohn’s disease treatment. Market players are focusing on to develop new products that can treat Crohn’s disease. For instance, mongersen, is investigational therapy for the treatment of crohn’s disease, is being developed by Celgene Corporation in phase 3 clinical trials. Considering the foreseen factors Crohn’s disease treatment market is projected to have a lucrative opportunity for market players.

Geographically Crohn’s disease treatment market is divided into five key regions, i.e. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to contribute major share owing to increase in R&D activity and biologics approval to treat autoimmune disease. Furthermore, increase in prevalence and incidence of the Crohn’s disease are expected to drive the growth of the market. According to Crohn’s and Colitis Foundation of America 700,000 have crohn’s diseases in between 1992-2004, and 74% increase in doctor office visits due to crohn’s disease. Asia-Pacific region is expected to create significant growth opportunities for the market players owing to develop infrastructure, R&D activities related to biologics and increase in prevalence of Crohn’s disease in the region. Developing countries such as India and China expected to show the fastest growth owing to increase in R&D investment and healthcare expenditure in these countries

Some of the market players in Crohn’s disease treatment market are Allergan, Inc. (U.S.), AbbVie Inc., (U.S.), Takeda Pharmaceutical Company Limited (Japan), Bayer AG (Switzerland), UCB S.A. (Belgium), Perrigo Company plc (Ireland), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), and Ferring B.V. (Switzerland) to name a few

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CROHN’S DISEASE TREATMENT MARKET INTRODUCTION

2.1. Global Crohn’s Disease Treatment Market – Taxonomy
2.2. Global Crohn’s Disease Treatment Market –Definitions
  2.2.1. Drug Class
  2.2.2. Distribution Channel

3. GLOBAL CROHN’S DISEASE TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Crohn’s Disease Treatment Market Dynamic Factors - Impact Analysis

4. GLOBAL CROHN’S DISEASE TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis

5. GLOBAL CROHN’S DISEASE TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

5.1. Antibiotics
  5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Anti-Diarrheal
  5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Immune System Suppressants
  5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Analgesics
  5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Anti-Inflammatory Drugs
  5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Monoclonal Antibodies
  5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis

6. GLOBAL CROHN’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

6.1. Hospital Pharmacies
  6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacies
  6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Online Pharmacies
  6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL CROHN’S DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

7.1. North America
  7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Europe
  7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
  7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Latin America
  7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
  7.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.5.3. Market Opportunity Analysis
7.6. Global Crohn’s Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Region, 2017 – 2023

8. NORTH AMERICA CROHN’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

8.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  8.1.1. Antibiotics
  8.1.2. Anti-Diarrheal
  8.1.3. Immune System Suppressants
  8.1.4. Analgesics
  8.1.5. Anti-Inflammatory Drugs
  8.1.6. Monoclonal Antibodies
8.2. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  8.2.1. Hospital Pharmacies
  8.2.2. Retail Pharmacies
  8.2.3. Online Pharmacies
8.3. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  8.3.1. U.S.
  8.3.2. Canada
8.4. North America Crohn’s Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
8.5. North America Crohn’s Disease Treatment Market Dynamics – Trends

9. EUROPE CROHN’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

9.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Antibiotics
  9.1.2. Anti-Diarrheal
  9.1.3. Immune System Suppressants
  9.1.4. Analgesics
  9.1.5. Anti-Inflammatory Drugs
  9.1.6. Monoclonal Antibodies
9.2. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.2.1. Hospital Pharmacies
  9.2.2. Retail Pharmacies
  9.2.3. Online Pharmacies
9.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Germany
  9.3.2. UK
  9.3.3. France
  9.3.4. Spain
  9.3.5. Italy
  9.3.6. Russia
  9.3.7. Poland
  9.3.8. Rest of Europe
9.4. Europe Crohn’s Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
9.5. Europe Crohn’s Disease Treatment Market Dynamics – Trends

10. ASIA-PACIFIC CROHN’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

10.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Antibiotics
  10.1.2. Anti-Diarrheal
  10.1.3. Immune System Suppressants
  10.1.4. Analgesics
  10.1.5. Anti-Inflammatory Drugs
  10.1.6. Monoclonal Antibodies
10.2. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.2.1. Hospital Pharmacies
  10.2.2. Retail Pharmacies
  10.2.3. Online Pharmacies
10.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Japan
  10.3.2. China
  10.3.3. India
  10.3.4. ASEAN
  10.3.5. Australia & New Zealand
  10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Crohn’s Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
10.5. Asia-Pacific Crohn’s Disease Treatment Market Dynamics – Trends

11. LATIN AMERICA CROHN’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

11.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Antibiotics
  11.1.2. Anti-Diarrheal
  11.1.3. Immune System Suppressants
  11.1.4. Analgesics
  11.1.5. Anti-Inflammatory Drugs
  11.1.6. Monoclonal Antibodies
11.2. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.2.1. Hospital Pharmacies
  11.2.2. Retail Pharmacies
  11.2.3. Online Pharmacies
11.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Brazil
  11.3.2. Mexico
  11.3.3. Argentina
  11.3.4. Venezuela
  11.3.5. Rest of Latin America
11.4. Latin America Crohn’s Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
11.5. Latin America Crohn’s Disease Treatment Market Dynamics – Trends

12. MIDDLE EAST AND AFRICA CROHN’S DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

12.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Antibiotics
  12.1.2. Anti-Diarrheal
  12.1.3. Immune System Suppressants
  12.1.4. Analgesics
  12.1.5. Anti-Inflammatory Drugs
  12.1.6. Monoclonal Antibodies
12.2. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.2.1. Hospital Pharmacies
  12.2.2. Retail Pharmacies
  12.2.3. Online Pharmacies
12.3. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Gulf Cooperation Council (GCC) Countries
  12.3.2. Israel
  12.3.3. South Africa
  12.3.4. Rest of MEA
12.4. MEA Crohn’s Disease Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, and Country, 2017 – 2023
12.5. MEA Crohn’s Disease Treatment Market Dynamics – Trends

13. COMPETITION LANDSCAPE

13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  13.2.1. Allergan, Inc. (U.S.)
  13.2.2. AbbVie Inc., (U.S.)
  13.2.3. Takeda Pharmaceutical Company Limited (Japan)
  13.2.4. Bayer AG (Switzerland)
  13.2.5. UCB S.A. (Belgium)
  13.2.6. Perrigo Company plc (Ireland)
  13.2.7. Pfizer Inc. (US)
  13.2.8. Johnson & Johnson Services, Inc. (US)
  13.2.9. Ferring B.V. (Switzerland)

14. RESEARCH METHODOLOGY

15. KEY ASSUMPTIONS AND ACRONYMS